SEROLOGIC RESPONSE AND SAFETY AFTER THIRD DOSE OF THE COVID-19 BNT162B2 VACCINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Hadar Edelman-Klapper  ¹     Keren Masha Rabinowitz  ¹     Eran Zittan  ²     Ariella Bar Gil Shitrit  ³     Idan Goren  ³     Irit Avni-Biron  ³     Jacob E. Ollech  ³     Lev Lichtenstein  ⁴     Hagar Banai-Eran  ⁴     Henit Yanai  ⁴     Yifat Snir  ⁴     Maor H. Pauker  ⁴     Adi Friedenberg  ⁴     Adva Levy-Barda  ⁴     Arie Segal  ⁵     Yelena Broitman  ⁵     Eran Maoz  ⁶     Baruch Ovadia  ⁷     Maya Aharoni Golan  ⁷     Eyal Shachar  ⁸     Shomron Ben-Horin  ⁸     Michal Mor  ⁸     Haim Ben Zvi  ⁸     Tsachi-Tsadok Perets  ⁸     Rami Eliakim  ⁸     Revital Barkan  ⁸     Michal Navon  ⁸     Meital Gal-Tanamy  ⁹     Natalia T. Freund  ⁹     Sophy Goren  ⁹     Dani Cohen  ⁹     Iris Dotan  ^9    
1 Rabin Medical Center, Petah Tikva, Israel
² Emek Medical Center, Afula, Israel
³ Shaare Zedek Medical Center, Jerusalem, Israel
⁴ Clalit Health Services, Petah Tikva, Israel
⁵ Soroka University Medical Center, Beer-Sheva, Israel
⁶ Clalit Health Services, Tel Aviv, Israel
⁷ Hillel Yaffe Medical Center, Hadera, Israel
⁸ Tel Aviv University, Tel Aviv, Israel
⁹ Bar-Ilan University, Safed, Israel

Session
Covid-19 in IBD (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)